The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Doxorubicin, cisplatin, and ifosfamide (API) as first-line therapy for relapsed or metastatic uterine leiomyosarcoma.
Julien Hadoux
No relevant relationships to disclose
Annie Rey
No relevant relationships to disclose
Pierre Duvillard
No relevant relationships to disclose
Catherine Lhomme
No relevant relationships to disclose
Corinne Balleyguier
No relevant relationships to disclose
Christine Haie Meder
No relevant relationships to disclose
Philippe Morice
No relevant relationships to disclose
Sebastien Gouy
No relevant relationships to disclose
Catherine Uzan
No relevant relationships to disclose
Renaud Mazeron
No relevant relationships to disclose
Christine Larue
No relevant relationships to disclose
Patricia Pautier
No relevant relationships to disclose